Exabis Library
Welcome to the e-CCO Library!
P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P682: Antibiotic resistome profiles of fecal Escherichia coli isolates in association with Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P682: Development of anti-ustekinumab antibodies is an independent factor associated to loss of response to ustekinumab therapy in IBD patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P682: GO-CARE: a prospective multi-centre observational study of golimumab effectiveness and quality of life in a real life UC patient population in Italy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P682: Predictors of response to biologics in Ulcerative Colitis: A population-based study from the epi-IIRN
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P682: Risk factors and clinical outcome in IBD patients with melanoma
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P682: Role of laboratory markers in paediatric inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P683 Infliximab, adalimumab and vedolizumab levels are not altered by pregnancy progression in IBD patients and neonatal vedolizumab levels are lower than in mothers: Results from the PICCOLO study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P683: Discontinuation of infliximab treatment: a comparison between IBD patients who retransitioned to originator and those who remained on biosimilar
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P683: Higher serum golimumab concentrations are significantly associated with combined clinical-biochemical remission during maintenance therapy: results from the GO-LEVEL study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P683: Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF-α treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P683: Maintenance of deep remission in patients with ulcerative colitis treated with thiopurines after withdrawal of the drug: Perspective real-life experience of a single centre
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P683: Patients with newly diagnosed fistulizing perianal Crohn's disease have a distinct microbial signature
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P683: Risk factors for fatigue in IBD patients.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P684: A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P684: Extra intravenous reinduction of ustekinumab on an already shortening interval is an effective optimisation strategy for patients with refractory Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P684: Increased risk of cardiovascular disease and high risk profiles compatible with metabolic syndrome in patients with Inflammatory Bowel Disease: a cross-sectional analysis of matched cohorts
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P684: Multiplex Gastrointestinal Pathogen Panel Testing is Associated with Higher Rates of Inflammatory Bowel Disease Therapy Escalation in Patients Hospitalised with Flare
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P684: Sleep disturbances in IBD patients without sedative therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM